ASEAN CSDT Dossier Requirements for Thailand: Full, Abridged and Reliance

Must Thailand use the CSDT? For Classes 2-4, yes: submissions must follow the ASEAN Common Submission Dossier Template (ASEAN CSDT). Class 1 follows a simplified route and needs only basic materials such as the label, IFU, product specifications, device description, materials, declaration of conformity and letter of authorisation. Thailand is a member of the AMDD, and the CSDT is the standard format for the technical dossier.

1. Key takeaways

The three routes differ from one another in well-defined, knowable ways, and the Class 2-4 document matrix published on the Thai FDA website spells them out. The essentials follow.

• Classes 2-4 must submit under the ASEAN CSDT; Class 1 uses a simplified document set with no CSDT obligation.
• All three routes share a common core of items: label/IFU, executive summary, device description, Essential Principles, manufacturer information, quality system certificate, declaration of conformity and letter of authorisation — eight common items that must be prepared no matter which route is chosen.
• The Abridged route exempts the verification and validation summary and the risk analysis, but requires four additions: the intended use / indications declaration, the market history declaration, the safety declaration, and evidence of reference authority approval.
• The Reliance with HSA route keeps the full technical set and adds five HSA-related documents: the HSA-approved change notifications, the regulatory reliance participation letter, the HSA approval evidence, the consent letter, and consistency between the Thai FDA and HSA CSDT versions.
• The Essential Principles section is the most error-prone part of the CSDT. It is not a declaration of conformity in the abstract: it requires item-by-item mapping with an index of evidence supporting each claim. A single sentence asserting conformity with the ASEAN Essential Principles is a classic rejection formula.
• The recommended build order is to establish the CSDT base to the Full route checklist first, then subtract according to the actual route — Abridged removes two items and adds three declarations; Reliance adds five dependency documents.

2. Legal basis

The matrix below reproduces the Class 2-4 document comparison published on the Thai FDA website (tick means required, dash means not required). The classification obligations rest on the MoPH classification notification B.E. 2562 (2019), fees are governed by the ministerial regulation on medical device fees B.E. 2563 (2020) and the MoPH fee announcement B.E. 2564 (2021), and the Reliance column derives from the Thai FDA reliance announcement of June 4, 2024 (B.E. 2567).

3. Expert insights

The matrix has three concrete uses. First, look at the exemptions before choosing a route: the Abridged route waives the verification and validation summary and the risk analysis, but the waiver must be bought with three declarations. Second, the essence of Reliance is not submitting less but submitting more evidence of dependency: five categories of HSA-related documents are added, and keeping the Thai FDA CSDT identical to the HSA version, including later change notifications, is a standing obligation for the life of the certificate. Third, the common items across all three routes number eight — label, IFU, executive summary, device description, Essential Principles, manufacturer information, quality system certificate, declaration of conformity and letter of authorisation — and these are the base documents that must be prepared regardless of route. Building them once, properly, pays off under every pathway.

On the most common failure point: the Essential Principles section demands item-by-item mapping with an index pointing to conformity evidence for each principle. Chinese-language materials often reduce this section to a single sentence stating that the product conforms to the ASEAN Essential Principles of safety and performance — a formulation that reliably invites rejection. Reviewers want to trace each principle to test reports, risk documentation or other objective evidence, and the index structure exists precisely to make that traceable.

4. Practical recommendations

• Build the CSDT base according to the complete Full route checklist first, then subtract for the actual route: Abridged deletes two items and adds three declarations; Reliance adds five dependency documents.
• This order matters: a base built first and then trimmed guarantees that a later route switch — for example losing Reliance eligibility — does not require starting the dossier from scratch.
• Treat the Essential Principles as an indexed evidence table, with each principle mapped to specific objective evidence, and review that mapping internally before submission.
• Keep the eight common items continuously maintained and current, since they serve every route and any future transfer or pathway change.
• If the Abridged route is intended, prepare the market history and safety record substantiation with the same rigour as technical documents, because the declarations are the price of the exemptions.
• If Reliance with HSA is intended, set up version control between the Thai FDA and HSA CSDT versions from day one, including change notifications.

5. Verification checklist

• □ Thai FDA website Class 2-4 document checklist matrix (Full / Abridged / Reliance with HSA)
• □ ASEAN CSDT template structure
• □ Thai FDA reliance announcement (June 4, 2024, B.E. 2567)
• □ Thai FDA website Class 1 simplified document checklist
• □ Ministerial regulation on medical device fees B.E. 2563 (2020) and MoPH fee announcement B.E. 2564 (2021)

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Thailand. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the Thai FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com